XNCR
Xencor shares rise on data from XmAb819 trial
Xencor released updated results from a Phase 1 study on its XmAb819 bispecific antibody for kidney cancer. Positive data led to a strong market reaction.
XNCR news
Latest 2 stories · newest Oct 26, 2026
XNCR
Xencor announces Phase 1 expansion data in renal cell carcinoma and opens healthy subject study for lead bispecific antibody.
Xencor reported Q2 2026 financial results and announced that data from XmAb819 expansion cohorts in clear cell renal cell carcinoma will be presented at ESMO 2026; additionally, the company initiated a first-in-human study for its first xenlock bispecific antibody, XmAb412.
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.
The same XNCR feed as JSON for your bot or app:
GET https://api.brieftape.com/v1/tickers/XNCR/newsSTART FREE